Dr. Christopher Larosa, MD

NPI: 1063623544
Total Payments
$3,334
2024 Payments
$750.00
Companies
6
Transactions
15
Medicare Patients
43
Medicare Billing
$13,641

Payment Breakdown by Category

Consulting$3,225 (96.7%)
Food & Beverage$104.79 (3.1%)
Education$3.74 (0.1%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $3,225 7 96.7%
Food and Beverage $104.79 5 3.1%
Education $3.74 3 0.1%

Top Paying Companies

Company Total Records Latest Year
Merck Sharp & Dohme LLC $3,225 7 $0 (2024)
Alexion Pharmaceuticals, Inc. $30.11 1 $0 (2017)
Mallinckrodt LLC $28.01 1 $0 (2017)
Leadiant Biosciences, Inc. $22.23 4 $0 (2017)
Novartis Pharmaceuticals Corporation $14.57 1 $0 (2017)
BAXTER HEALTHCARE $13.61 1 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2024 $750.00 1 Merck Sharp & Dohme LLC ($750.00)
2022 $450.00 1 Merck Sharp & Dohme LLC ($450.00)
2021 $450.00 1 Merck Sharp & Dohme Corporation ($450.00)
2020 $450.00 1 Merck Sharp & Dohme Corporation ($450.00)
2019 $375.00 1 Merck Sharp & Dohme Corporation ($375.00)
2018 $375.00 1 Merck Sharp & Dohme Corporation ($375.00)
2017 $483.53 9 Merck Sharp & Dohme Corporation ($375.00)

All Payment Transactions

15 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
12/04/2024 Merck Sharp & Dohme LLC Consulting Fee Cash or cash equivalent $750.00 General
02/25/2022 Merck Sharp & Dohme LLC Consulting Fee Cash or cash equivalent $450.00 General
03/10/2021 Merck Sharp & Dohme Corporation Consulting Fee Cash or cash equivalent $450.00 General
02/26/2020 Merck Sharp & Dohme Corporation Consulting Fee Cash or cash equivalent $450.00 General
04/10/2019 Merck Sharp & Dohme Corporation Consulting Fee Cash or cash equivalent $375.00 General
03/21/2018 Merck Sharp & Dohme Corporation Consulting Fee Cash or cash equivalent $375.00 General
08/19/2017 Alexion Pharmaceuticals, Inc. Strensiq (Drug) Food and Beverage In-kind items and services $30.11 General
Category: Endocrinology
07/21/2017 BAXTER HEALTHCARE Renal - Prismaflex System (Device) Food and Beverage In-kind items and services $13.61 General
Category: Renal
05/26/2017 Mallinckrodt LLC ACTHAR (Biological) Food and Beverage In-kind items and services $28.01 General
Category: AUTOIMMUNE AND RARE DISEASE
05/19/2017 Leadiant Biosciences, Inc. Cystaran (Drug) Food and Beverage In-kind items and services $18.49 General
Category: Ophthalmic
05/19/2017 Leadiant Biosciences, Inc. Cystaran (Drug) Education In-kind items and services $3.34 General
Category: Ophthalmic
05/19/2017 Leadiant Biosciences, Inc. Cystaran (Drug) Education In-kind items and services $0.20 General
Category: Ophthalmic
05/19/2017 Leadiant Biosciences, Inc. Cystaran (Drug) Education In-kind items and services $0.20 General
Category: Ophthalmic
04/21/2017 Novartis Pharmaceuticals Corporation AFINITOR (Drug) Food and Beverage In-kind items and services $14.57 General
Category: ONCOLOGY
03/03/2017 Merck Sharp & Dohme Corporation Consulting Fee Cash or cash equivalent $375.00 General

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2022 1 15 36 $17,974 $4,672
2021 1 16 39 $18,862 $5,245
2020 1 12 37 $17,410 $3,724
Total Patients
43
Total Services
112
Medicare Billing
$13,641
Procedure Codes
3

All Medicare Procedures & Services

3 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 15 36 $17,974 $4,672 26.0%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 16 39 $18,862 $5,245 27.8%
99215 Established patient office or other outpatient, visit typically 40 minutes Office 2020 12 37 $17,410 $3,724 21.4%

About Dr. Christopher Larosa, MD

Dr. Christopher Larosa, MD is a Pediatric Nephrology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1063623544.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Larosa, MD has received a total of $3,334 in payments from pharmaceutical and medical device companies, with $750.00 received in 2024. These payments were reported across 15 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($3,225).

As a Medicare-enrolled provider, Larosa has provided services to 43 Medicare beneficiaries, totaling 112 services with total Medicare billing of $13,641. Data is available for 3 years (2020–2022), covering 3 distinct procedure/service records.

Practice Information

  • Specialty Pediatric Nephrology
  • Location Philadelphia, PA
  • Active Since 05/25/2007
  • Last Updated 12/04/2018
  • Taxonomy Code 2080P0210X
  • Entity Type Individual
  • NPI Number 1063623544

Products in Payments

  • Strensiq (Drug) $30.11
  • ACTHAR (Biological) $28.01
  • Cystaran (Drug) $22.23
  • AFINITOR (Drug) $14.57
  • Renal - Prismaflex System (Device) $13.61

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Nephrology Doctors in Philadelphia